LOSEC CAPSULE (DELAYED RELEASE)
Land: Canada
Språk: engelsk
Kilde: Health Canada
Preparatomtale
(SPC)
17-10-2023
Noen dokumenter for dette produktet er ikke tilgjengelig for øyeblikket, du kan sende en forespørsel til kundeservicen vår, og vi vil varsle deg så snart vi kan få dem.
Send forespørsel.
Send forespørsel.
Aktiv ingrediens:
OMEPRAZOLE
Tilgjengelig fra:
CHEPLAPHARM ARZNEIMITTEL GMBH
ATC-kode:
A02BC01
INN (International Name):
OMEPRAZOLE
Dosering :
20MG
Legemiddelform:
CAPSULE (DELAYED RELEASE)
Sammensetning:
OMEPRAZOLE 20MG
Administreringsrute:
ORAL
Enheter i pakken:
28
Resept typen:
Prescription
Terapeutisk område:
PROTON-PUMP INHIBITORS
Produkt oppsummering:
Active ingredient group (AIG) number: 0121643001; AHFS:
Autorisasjon status:
APPROVED
Autorisasjon dato:
2020-11-02
Preparatomtale
_Product Monograph _
_Date: September 2023 _
_LOSEC (omeprazole delayed release capsules) _
_Page 1 of 43_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
LOSEC®
Omeprazole delayed release capsules
Capsules (delayed release), 20 mg omeprazole, oral
Proton Pump Inhibitor
MANUFACTURER:
CHEPLAPHARM Arzneimittel GmbH
Ziegelhof 24
17489 Greifswald
Germany
IMPORTER / DISTRIBUTOR:
Xediton Pharmaceuticals Inc.
2020 Winston Park Drive, Suite 402
Oakville, Ontario L6H 6X7
Tel: 1-888-XEDITON (933-4866)
DATE OF INITIAL AUTHORIZATION:
JAN 13, 1989
DATE OF REVISION:
OCT 17, 2023
Submission Control Number: 275360
LOSEC
®
is a registered trademark.
_Product Monograph _
_Date: September 2023 _
_LOSEC (omeprazole delayed release capsules) _
_Page 2 of 43_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS
10/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
..........................................................................................................
2
TABLE OF CONTENTS
............................................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
....................................................................................
4
1
INDICATIONS
...........................................................................................................................
4
1.1
Pediatrics
...............................................................................................................................
4
1.2
Geriatrics
...............................................................................................................................
4
2
CONTRAINDICATIONS
..............................................................................................................
4
4
DOSAGE AND ADMINISTRATION
..............................................................................................
4
4.1
Dosing Conside
Les hele dokumentet
